Asuragen to Present Expansion of Next-Generation Sequencing Portfolio at American Association of Cancer Research Annual Meeting
Austin, Texas – April 18, 2016 – Asuragen Inc., a global molecular diagnostics company, will showcase its newest Next-Generation Sequencing (NGS) technology capability in the Journal of Visualized Experiments and at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 18th. The data highlight the flexibility of Asuragen’s NGS-in-a-Box™ technology for DNA and RNA sequencing, and its applicability to the routine laboratory and non-small cell lung cancer (NSCLC). The QuantideX® NGS RNA Lung Cancer Panel*, which will be commercially available in the third quarter of 2016, represents a significant improvement for clinical researchers with a greater than 50% improvement in turn-around time and a more than 30% reduction in hands-on time and associated costs.
Data generated in collaboration with M.D. Anderson Cancer Center (Abstract #1389 “A Unified and Streamlined Targeted Sequencing System for the Quantification of DNA Mutations and RNA Expression Markers in Lung Cancer”) demonstrate strong analytical performance of the QuantideX® NGS System with challenging clinical samples. Results from the analyses of over 100 NSCLC FFPE patient samples reveal profiles of RNA translocations and DNA mutations consistent with lung adenocarcinoma and squamous cell carcinoma. These findings highlight how Asuragen’s NGS chemistries and software can be adapted to new content, as is also being demonstrated in a companion diagnostic project underway in oncology with a biotech partner and in collaboration with Illumina. This companion diagnostic partnership is one of Asuragen’s more than 20 active assay and product development collaborations with biotech and pharma partners in the clinical areas of inherited disease, oncology, infectious disease and neurodegenerative disease.
“Asuragen has developed a unique NGS system that overcomes a range of technical, sample and workflow hurdles. This modular NGS approach enables rapid development of new targeted NGS assays. Our novel NGS product development platform is highly flexible and adaptable to meet pharma’s and clinical researchers’ technical and regulatory needs. As importantly, our design and development process ensures a product with simplified workflows and optimized ease-of-use for laboratories that have implemented them in routine settings” said Matthew McManus, MD, PhD, Asuragen’s President and CEO. “Asuragen’s combination of proprietary core molecular technologies and strong portfolio of third party instrument access agreements has positioned us well to become the partner of choice for companion diagnostic development projects.”
Visit Asuragen at AACR at Booth #2738 for more details on the QuantideX® NGS System, DNA and RNA Panels and companion diagnostic partnering.
The development of the QuantideX® RNA Lung Cancer Panel was funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Product Development Research grant.
*For research purposes only. Not for diagnostic use.
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. For more information, visit www.asuragen.com
SVP, Corporate Development and CFO